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Abstract
With the functional demonstration of a role in erythrocyte invasion by Plasmodium falciparum parasites, implications in the
aetiology of common conditions that prevail in individuals of African origin, and a wealth of pharmacological knowledge,
the stimulatory G protein (Gs) signal transduction pathway presents an exciting target for anti-malarial drug intervention.
Having previously demonstrated a role for the G-alpha-s gene, GNAS, in severe malaria disease, we sought to identify other
important components of the Gs pathway. Using meta-analysis across case-control and family trio (affected child and
parental controls) studies of severe malaria from The Gambia and Malawi, we sought evidence of association in six Gs
pathway candidate genes: adenosine receptor 2A (ADORA2A) and 2B (ADORA2B), beta-adrenergic receptor kinase 1
(ADRBK1), adenylyl cyclase 9 (ADCY9), G protein beta subunit 3 (GNB3), and regulator of G protein signalling 2 (RGS2). Our
study amassed a total of 2278 cases and 2364 controls. Allele-based models of association were investigated in all genes,
and genotype and haplotype-based models were investigated where significant allelic associations were identified.
Although no significant associations were observed in the other genes, several were identified in ADORA2A. The most
significant association was observed at the rs9624472 locus, where the G allele (,20% frequency) appeared to confer
enhanced risk to severe malaria [OR= 1.22 (1.09–1.37); P= 0.001]. Further investigation of the ADORA2A gene region is
required to validate the associations identified here, and to identify and functionally characterize the responsible causal
variant(s). Our results provide further evidence supporting a role of the Gs signal transduction pathway in the regulation of
severe malaria, and request further exploration of this pathway in future studies.
Citation: Auburn S, Fry AE, Clark TG, Campino S, Diakite M, et al. (2010) Further Evidence Supporting a Role for Gs Signal Transduction in Severe Malaria
Pathogenesis. PLoS ONE 5(4): e10017. doi:10.1371/journal.pone.0010017
Editor: Philip Awadalla, University of Montreal, Canada
Received July 25, 2009; Accepted February 11, 2010; Published April 1, 2010
This is an open-access article distributed under the terms of the Creative Commons Public Domain declaration which stipulates that, once placed in the public
domain, this work may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose.
Funding: The genetic component of this research was funded by a Medical Research Council (UK) (http://www.mrc.ac.uk/index.htm) grant to Prof. Dominic
Kwiatkowski and a National Institutes of Health (USA)(http://www.nih.gov/) grant to Prof. Kasturi Haldar. SA was supported by a PhD studentship from the
Medical Research council (UK) (http://www.mrc.ac.uk/index.htm). AEF was funded by a Wellcome Trust Training Fellowship (http://www.wellcome.ac.uk/). TC was
funded by the Bill and Melinda Gates Foundation (http://www.gatesfoundation.org/Pages/home.aspx). SC was funded by a Marie-Curie intra-European fellowship
(FP6) (http://cordis.europa.eu/mariecurie-actions/eif/home.html). MD was supported by a training fellowship from the International Atomic Energy Agency
(http://www.iaea.org/). Sample collection in Malawi was supported by NIH grant 5R01AI034969-09 (http://www.nih.gov/). The funders had no role in study design,
data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: sa3@sanger.ac.uk
Introduction
As an obligatory route to blood parasitaemia, erythrocyte
invasion is an essential gateway to malaria disease and a key target
for disease intervention. However, we still have only a limited
understanding of the molecular mechanisms underlying erythro-
cyte invasion by Plasmodium falciparum, the most virulent species of
human malaria parasite, and their impact at the disease level
(review in [1]).
A wide spectrum of clinical outcomes is observed in response to
malaria infection in endemic regions. While some infected
individuals remain asymptomatic, others may suffer mild symp-
toms of disease, and a small proportion of infections progress to
severe, life-threatening complications [2]. As well as environmen-
tal and parasite determinants, a number of host factors influence
individual response to malarial infection including age/immune
status and genetic makeup. These factors may influence the
outcome at various stages in the transition from initial infection to
blood parasitaemia, fever, severe disease, and death. Thus, factors
which promote progression at any of these stages should be
enriched in individuals suffering severe disease and death. Case-
control association studies using severe disease cases, therefore,
present an effective tool to identify host genetic factors regulating
any of the earlier transitions in disease progression, including
determinants of erythrocyte invasion which regulate blood
parasitaemia levels.
Harrison and colleagues demonstrated a role for the host
erythrocyte stimulatory G protein (Gs) pathway in erythrocyte
invasion [3]. Using peptides designed to disrupt the interaction
between the G-alpha-s subunit of the Gs protein and the beta-2-
PLoS ONE | www.plosone.org 1 April 2010 | Volume 5 | Issue 4 | e10017
adrenergic receptor, a Gs protein-coupled receptor, reduced
erythrocyte invasion by P. falciparum parasites and subsequently
lower parasitaemia was observed in vitro [3]. Seeking evidence of
an impact of these Gs signal transduction-related events on disease
progression, we previously demonstrated association between
polymorphism in the gene encoding G-alpha-s (GNAS) and severe
malaria disease using a case-control association approach [4]. The
demonstration of a disease-regulatory role at the GNAS locus
warranted further investigation of the Gs pathway to enhance our
understanding of the disease mechanism(s) involved and to identify
other components which might present suitable targets for anti-
malarial drug intervention. Indeed, owing to implications in
common disorders such as hypertension and diabetes, the
pharmacology of the Gs pathway is well defined [5], meriting it
high feasibility for anti-malarial drug intervention. With the
availability of the Sequenom iPLEX platform (www.sequenom.
com) and the opportunity for lower cost and higher throughput
genotyping (,10-fold increase in SNP number) relative to the
previous Sequenom (hME) platform, we were able to undertake
economic genotyping in a larger selection of genes, allowing
further interrogation of the Gs pathway to identify other disease-
regulatory candidates that might present suitable targets for anti-
malarial drug intervention.
G protein pathways provide a means for intracellular compo-
nents to respond appropriately to extracellular stimuli [6].
Different stimuli may require different signal transduction events
and subsequent effector responses, and the specificity in the signal
transduction systems resides in the G protein coupled receptor
(GPCR). Gs proteins transduce signals from several GPCRs to
adenylyl cyclases which produce cAMP. Gs GPCRs include
adenosine receptor alpha 2A and 2B (ADORA2A and
ADORA2B), and beta-1- and beta-2- adrenergic receptors
(ADRB1 and ADRB2). Beta-adrenergic receptors are activated
by various catecholamines, while adenosine is the preferred
agonist for ADORA2A and ADORA2B. Activation of the
pathway is initialized by an agonist binding to the appropriate
GPCR which has greater affinity for the Gs protein. In the basal
state, Gs proteins are heterotrimeric, comprising 3 subunits, alpha,
beta and gamma, with GDP bound to the alpha subunit.
Stimulation of the Gs protein by interaction with the GPCR
results in exchange of GTP for GDP. The GTP-bound G-alpha-s
subunit (GNAS) dissociates from the beta-gamma dimer and
activates adenylyl cyclase (e.g. ADCY9), which then converts ATP
to cAMP. The second messenger, cAMP, activates effector
molecules such as protein kinase A, which elicit an appropriate
response to the initial agonist stimulation.
Negative feedback processes regulate the Gs pathway in order to
prevent excessive cell signalling. Following dissociation from the
G-alpha-s subunit, the beta-gamma dimer binds and translocates a
G protein coupled receptor kinase such as the beta-adrenergic
receptor kinase 1 (ADRBK1) to the membrane [7]. At the
membrane, the kinase phosphorylates the agonist-activated GPCR
which then complexes with arrestin protein preventing further
coupling to the G protein. The free G-alpha-s subunit is
deactivated by a regulator of G protein signalling molecule
(RGS) such as RGS2, which binds to the G-alpha-s subunit and
acts as a GTPase-activating protein to attenuate signalling of the
GTP-bound G-alpha-s subunit [8]. RGS2 also appears to interact
with ADCY to reduce cAMP production [9].
The inhibitory G (Gi) protein pathway also opposes the effects
of the Gs pathway, having an inhibitory effect on adenylyl cyclase
and cAMP production. A well studied component of this pathway
is the Gi beta subunit 3 (GNB3), which has been implicated in
complex disorders such as hypertension [10,11].
Using meta-analysis pooled across four association studies
(Malawi case-control (unrelated cases and controls), Malawi family
trio (affected child and parental controls), Gambian case-control
and Gambian trio), we tested SNP associations with severe malaria
in six genes related to the Gs pathway; adenosine receptor alpha 2A
and 2B (ADORA2A, ADORA2B), beta-adrenergic receptor kinase 1
(ADRBK1), regulator of G protein signalling 2 (RGS2), adenylyl
cyclase 9 (ADCY9), and G-protein-beta 3 (GNB3). A meta-analysis
approach was chosen to enhance sample size whilst allowing for
heterogeneity between studies. Owing to the challenges of collecting
severe malaria cases in African study sites, large sample sizes are
difficult to obtain [12]. Despite efforts to standardize clinical
phenotyping across studies, owing to inter-population differences in
transmission patterns and demography, some heterogeneity still
remains in features such as the proportion of different severe
malaria subphenotypes (e.g. severe malarial anaemia).
Results
Assay performance
Allele frequencies for the assays (pre-filtered by quality
assessment on the HapMap Yoruba dataset) in the Gambian
and Malawian studies are presented in Table 1. All assays
demonstrated significant concordance with HWE (P,0.001) and
failure rates below 10% (results not presented).
Single-locus associations
Two of the four ADORA2A SNPs, rs9624472 and rs5751876,
demonstrated significant association with severe malaria, as illustrated
in Figures 1 and 2, respectively. The other two ADORA2A loci,
rs2267076 and rs3761422, demonstrated a trend of association
(0.05#P#0.1). A summary of the single-locus associations identified
in ADORA2A are presented in Table 2. The most significant
association was demonstrated at the rs9624472 locus (P=0.001),
with increased susceptibility to severe malaria conferred by the G
allele [OR=1.22 (1.09–1.37)] in an additive manner [AGOR=1.17
(1.02–1.36), P=0.029; GG OR=1.6 (1.13–2.26), P=0.008]. Upon
moving up- or down-stream of the rs9624472 locus, the strength of
associations weakened. Approximately 2.5 kb downstream of
rs9624472, the rs5751876 C allele conferred significant susceptibility
to severe malaria [OR=1.12 (1.02–1.23), P=0.024] with an
apparent recessive genotype effect [CT OR=1.03 (0.89–1.2),
P=0.652; CC OR=1.26 (1.01–1.57), P=0.042]. Four kilobases
upstream of rs9624472, the rs2267076 T allele demonstrated a trend
of susceptibility to severe malaria [OR=1.11 (1–1.23), P=0.051]
and, further upstream (8 kb), the rs3761422 T demonstrated a
weaker trend of susceptibility to severe malaria [OR=1.09 (0.99–
1.21), P=0.096]. No significant associations were demonstrated in
the other candidate genes (data in Table S1).
Multi-locus associations
Table 3 presents a summary of the meta-analysis associations
demonstrated with the common (.5%) ADORA2A haplotypes.
The two most significant haplotype associations concurred with
the single locus associations. The A2A-3 haplotype, which
comprises the risk-conferring rs9624472 (G) and rs5751876 (C)
alleles, accordingly demonstrated significant risk to severe malaria
[OR=1.21 (1.07–1.37), P=0.002]. Furthermore, the A2A-1
haplotype which comprises the protective alleles at rs9624472
(A) and rs5751876 (T) demonstrated significant protective from
severe malaria [OR=0.86 (0.77–0.95), P=0.003]. With a less
significant P-value, the A2A-2 haplotype, which comprises the
rs9624472 A and rs5751876 T alleles demonstrated risk to severe
malaria [OR=1.14 (1.02–1.28), P=0.019].
Gs Severe Malaria Association
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Discussion
Owing to implications in the aetiology of erythrocyte invasion
by P. falciparum [3,13], evidence of ethnic-specific variants
[14,15,16,17] possibly reflecting signatures of selection due to
malaria, and a wealth of pharmacological knowledge (review in
[5]), the Gs pathway presents an exciting target for anti-malarial
drug intervention. Having previously demonstrated a role for the
G-alpha-s gene, GNAS, in severe malaria disease [4], we sought to
identify other important components of the Gs pathway. In this
Table 1. SNP allele frequencies in the Gambian and Malawian case-control and family trio studies.
Gene Assay 1 Alleles Gambia CC Gambia Trio Malawi CC Malawi Trio
ADCY9 rs2238432 C/T 0.28 0.28 0.30 0.28
rs2230739 A/G 0.16 0.16 0.09 0.08
rs3730119 C/T 0.26 0.27 0.25 0.25
rs10775349 C/G 0.20 0.21 0.20 0.21
rs8047038 C/T 0.31 0.30 0.30 0.30
ADORA2A rs3761422 C/T 0.28 0.28 0.31 0.30
rs2267076 C/T 0.27 0.27 0.30 0.29
rs9624472 A/G 0.23 0.23 0.16 0.16
rs5751876 T/C 0.39 0.40 0.30 0.30
ADORA2B rs2535611 T/C 0.03 0.03 0.13 0.11
rs11654 G/C 0.32 0.30 0.22 0.23
rs2286796 G/A 0.37 0.30 0.22 0.23
rs2302416 G/A 0.29 0.30 0.31 0.33
ADRBK1 rs12285582 T/C 0.40 0.40 0.29 0.28
rs948988 G/A 0.39 0.40 0.28 0.27
rs7934433 C/T 0.14 0.12 0.28 0.30
GNB3 rs3759348 G/A 0.26 0.26 0.29 0.32
rs5443 T/C 0.18 0.16 0.16 0.16
rs5446 C/T 0.46 0.49 0.50 0.48
RGS2 rs7531013 G/A 0.44 0.42 0.24 0.26
rs2179652 T/C 0.44 0.38 0.25 0.25
rs2746073 T/A 0.02 0.01 0.06 0.05
1Major allele/minor allele. CC: Case-control.
doi:10.1371/journal.pone.0010017.t001
Figure 1. Forest plot of the odds ratios of severe malaria allelic
associations at the rs9624472 locus. Odds ratios of severe malaria
associations with the rs9624472 G allele are represented for each study
as a grey box with a horizontal line. The mid-point of the line represents
the odds ratio and the extreme points of the line represent the 95% CI.
The contribution of each study to the meta-analysis is represented by
the area of the grey box. The solid vertical line presents an odds-ratio of
1 (no association). The diamond at the bottom presents the overall
odds ratio and CI: OR= 1.22 (95% CI: 1.09–1.37), P = 0.001. Cochran’s Q-
test for heterogeneity on 4 degrees of freedom: P= 0.501.
doi:10.1371/journal.pone.0010017.g001
Figure 2. Forest plot of the odds ratios of severe malaria allelic
associations at the rs5751876 locus. Odds ratios of severe malaria
associations with the rs5751876 C allele are represented for each study
as a grey box with a horizontal line. The mid-point of the line represents
the odds ratio and the extreme points of the line represent the 95% CI.
The contribution of each study to the meta-analysis is represented by
the area of the grey box. The solid vertical line presents an odds-ratio of
1 (no association). The diamond at the bottom presents the overall
odds ratio and CI: OR= 1.12 (95% CI: 1.02–1.23), P = 0.024. Cochran’s Q-
test for heterogeneity on 4 degrees of freedom: P = 0.651.
doi:10.1371/journal.pone.0010017.g002
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study, and, to the best of our knowledge, the first candidate-based
investigation of ADORA2A in severe malaria, we demonstrate
significant association with this gene using meta-analysis across
case-control and TDT studies from The Gambia and Malawi.
We identified a pattern of association in the ADORA2A gene
whereby single-locus associations strengthened in significance with
increasing proximity to rs9624472, at which the most significant
association was observed (P=0.001). At this locus, the G allele
demonstrated enhanced susceptibility to severe malaria. With
respect to the rs9624472 locus, 2.5 kb downstream, the rs5751876
C allele demonstrated susceptibility to severe malaria (P=0.024);
4 kb upstream, the rs2267076 T allele demonstrated a trend of
susceptibility to severe malaria (P=0.051); and 8 kb upstream, the
rs3761422 T allele demonstrated a weak trend of susceptibility to
severe malaria (P=0.096). Using haplotype-based analysis, the two
most significant ADORA2A haplotype associations concurred with
the single-locus associations at rs9624472 and rs5751876; A2A-3
(CCGC) risk to severe malaria (P=0.002), and A2A-1 (CCAT)
protection from severe malaria (P=0.003). Association at A2A-2
(TTAT) demonstrated discordance with the single-locus effects of
rs9624472 A and rs5751876 T but at lower significance
(P=0.019). Further investigation of this region is required to
identify the true functional variant responsible for the observed
associations.
We used meta-analysis across the Gambian and Malawian TDT
and case-control studies in order to enhance our sample size.
Across the four studies, we amassed a total of 2278 cases and 2364
controls. A rough estimation of the power of this study to detect
the rs9624472 association was 97% at the 5% significance
Table 2. Summary of pooled single-locus associations
observed in the ADORA2A gene.
Assay Coordinate 1Test Variant OR (95% CI) Z-value (Pr)
rs3761422 23151226 T (C) 1.09 (0.99–1.21) 1.67 (0.096)
TT (CC) 1.19 (0.92–1.54) 1.32 (0.187)
CT (CC) 1.04 (0.90–1.19) 0.51 (0.611)
rs2267076 23155149 T (C) 1.11 (1.00–1.23) 1.95 (0.051)
TT (CC) 1.30 (0.99–1.71) 1.89 (0.058)
CT (CC) 1.04 (0.91–1.20) 0.56 (0.573)
rs9624472 23159285 G (A) 1.22 (1.09–1.37) 3.38 (0.001)
GG (AA) 1.60 (1.31–2.27) 2.65 (0.008)
AG (AA) 1.17 (1.02–1.36) 2.18 (0.029)
rs5751876 23161855 C (T) 1.12 (1.02–1.23) 2.26 (0.024)
CC (TT) 1.26 (1.01–1.57) 2.03 (0.042)
CT (TT) 1.03 (0.89–1.20) 0.45 (0.652)
Results refer to allele and genotype-based associations pooled across the four
studies: Gambia case-control, Gambia trios, Malawi case-control, and Malawi
trios.
1The test variant is followed by the alternative variant in brackets. Odds ratios
refer to the effect of the test variant. Significant z-values (P,0.05) are
presented in bold, trends of association (0.05#P#0.1) are presented in regular
font, and non-significant associations (P.0.1) are presented in dark grey.
Cochran’s Q-test for heterogeneity on 4 degrees of freedom P.0.05 in all tests.
doi:10.1371/journal.pone.0010017.t002
Table 3. Pooled haplotype-based odds ratios of association with severe malaria in the ADORA2A gene.
Haplotype Sequence1 Study Freq (%) 2 OR (95% CI) Z-value (Pr)
A2A-1 1111 (CCAT) Gambia CC 32.3 0.87 (0.74–1.03)
Gambia Trio 30.5 0.94 (0.76–1.17)
Malawi CC 40.1 0.84 (0.7–1.01)
Malawi Trio 34.2 0.67 (0.48–0.94)
Pooled 0.86 (0.77–0.95) 20.30 (0.003)
A2A-2 2211 (TTAT) Gambia CC 25.5 1.17 (0.98–1.4)
Gambia Trio 24.2 1.19 (0.92–1.53)
Malawi CC 28.7 1.08 (0.89–1.31)
Malawi Trio 28.5 1.2 (0.82–1.74)
Pooled 1.14 (1.02–1.28) 2.53 (0.019)
A2A-3 1122 (CCGC) Gambia CC 22.4 1.25 (1.03–1.5)
Gambia Trio 22.2 1.17 (0.91–1.51)
Malawi CC 15.4 1.17 (0.92–1.5)
Malawi Trio 18 1.25 (0.78–1.99)
Pooled 1.21 (1.07–1.37) 3.02 (0.002)
A2A-4 1112 (CCAC) Gambia CC 17.5 0.81 (0.66–1.01)
Gambia Trio 19.9 0.83 (0.63–1.09)
Malawi CC 14.9 0.99 (0.78–1.27)
Malawi Trio 18 1.19 (0.74–1.9)
Pooled 0.89 (0.78–1.02) 21.67 (0.094)
Significant z-values (P,0.05) are presented in bold.
11 =major allele, 2 =minor allele.
2Frequencies summed across cases and controls. The four haplotypes accounted for over 96% of the variation in each population. Cochran’s Q-test for heterogeneity on
4 degrees of freedom P.0.05 in all tests. CC: Case-control.
doi:10.1371/journal.pone.0010017.t003
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threshold [18]. Nonetheless, with MAF as low as 5%, even this
study was not sufficiently powered to detect allelic odds ratios of
,1.2 (probability of detection ,44%). With these levels of power,
no significant associations were demonstrated with ADCY9,
ADRBK1, ADORA2B, GNB3 or RGS2. Further investigation of
these genes in other populations and with greater sample size
should provide more conclusive evidence on their role in severe
malaria pathogenesis.
The results presented here have not been corrected for multiple
testing. The application of the Bonferroni correction in this study
is debatable as the candidate genes are members of the same
biological pathway and, thus, partially interdependent. Due to LD,
the SNPs within each gene also exert a measure of interdepen-
dence. If we correct the associations observed here by the number
of genes tested (6), the threshold for significance is P<0.008. At
this threshold, the rs9624472 allelic association (P=0.002), and
the A2A-1 (P=0.003) and A2A-3 (P=0.002) haplotype associa-
tions remain significant.
As a component of a signal pathway, it should be considered
that the ADORA2A associations presented here may represent a
complex network of interactions with other human genetic
variants in the Gs pathway such as the GNAS locus and, perhaps,
other pathways. Indeed, it is feasible that inter-gene interactions
may have masked our ability to detect possible associations at the
other loci investigated here. However, with regard to multiple
hypothesis testing, our study was not sufficiently powered to
investigate the numerous possible epistatic interactions between
the genes investigated here. In addition to other host genetic
factors, it should also be considered that a number of parasite
genetic factors and environmental factors may interact with
variants in the Gs pathway and, thus, influence the outcome of the
disease trait. Indeed, in the context of erythrocyte invasion, which
presents an intimate interaction between host and parasite
proteins, it is most likely that the composite of numerous parasite
and host genetic variants involved in the process ultimately
determines the overall rate of invasion. Unfortunately, owing
again to limited sample size, this study was underpowered to
investigate such variables.
The mechanism by which the ADORA2A associations presented
here might elicit a pathogenic effect in malaria disease remain
unclear. ADORA2A and ADORA2B are both adenosine-
activated GPCRs, the latter exhibiting lower affinity for this
agonist [19]. The Levels of extracellular adenosine rise in response
to metabolic stress and cell damage in conditions such as hypoxia,
inflammation and trauma [20,21]. In addition to erythrocytes,
ADORA2A is expressed in a wide range of tissues. Indeed,
activation of this receptor in various immune cells appears to
promote an anti-inflammatory cytokine profile [22]. A careful
balance of pro- and anti-inflammatory cytokine levels appears to
be critical to malaria outcome [23]. Thus, in addition to a
potential role in regulating erythrocyte invasion, ADORA2A may
mediate susceptibility to severe malaria via regulation of
inflammatory cytokine levels.
Accumulating evidence, including the ADORA2A association
reported in this study, indicates that the Gs signal transduction
pathway is involved in the regulation of malaria, and more
specifically, in the severe, life threatening manifestations of this
disease [3,4,13]. Thus, this pathway requires further exploration in
malaria studies. Indeed, further investigation of the ADORA2A
gene region is necessary to validate the associations identified here,
and to identify and functionally characterize the causal variant(s)
responsible for the signals of association. This should enhance our
understanding of how ADORA2A is involved in the regulation of
severe malaria pathology.
Materials and Methods
Ethics Statement
The Gambia Government/Medical Research Council Ethical
Committee approved the Gambian samples in this study. The
Malawian samples in this study were approved by the College of
Medicine Research and Ethics Committee. All samples were
obtained with informed written consent from a parent or
guardian.
Samples
Individuals were recruited in a clinical setting. Children under
the age of 12 years presenting with severe malaria at the Royal
Victoria Hospital in Banjul, The Gambia, and the Queen
Elizabeth Central Hospital in Blantyre, Malawi, were enrolled as
cases. Severe malaria was defined as severe malarial anaemia (SA),
cerebral malaria (CM), other severe complications such as
respiratory acidosis, and fatalities due to malaria infection. The
threshold for SA was a haemoglobin concentration ,5 g/dl in the
presence of P. falciparum asexual parasitaemia. CM was defined by
a Blantyre coma score #2, indicating unrousable coma not
attributable to convulsions, hypoglycaemia or meningitis in a
patient with P. falciparum parasitaemia [24]. Due to limited sample
size and, thus, power to detect association, severe malaria sub-
phenotypes were not investigated here (see Table S2). Population
controls for the case-control studies were obtained from umbilical
cord blood samples. In the family trios, the patients’ mother and
father were recruited as controls. Analysis was restricted to true
biological trios ($80% probability of being true parent-offspring
trios) confirmed using the Nuclear software package [25]. At each
study site, local teams managed sample collection and DNA
extraction. Genomic DNA samples were subject to whole genome
amplification using Multiple Displacement Amplification [26].
DNA from the HapMap Yoruba parental samples (http://www.
hapmap.org) was used to test the accuracy of the genotyping assays
and was extracted from lymphoblastoid cell lines provided by the
Coriell repository (Corriell Institute for Medical Research).
Gene selection
Genes were selected on account of one or more of the following
properties; implication in common disorders which prevail in
individuals of African origin possibly as a result of malaria
selection [27], such as essential hypertension and type 2 diabetes
mellitus [28,29,30,31] prevalence of ethnic-specific polymorphisms
which are polymorphic in individuals of African but not Caucasian
origin [17]; evidence of functional polymorphism altering signal
transduction [32,33]. We also attempted to investigate the beta-1
and beta-2-adrenergic receptors (ADRB1 and ADRB2), which have
previously been implicated in the regulation of P. falciparum
erythrocyte invasion [3]. However, possibly due to non-unique
sequence, we were unable to design accurate genotyping assays on
the Sequenom iPLEX and hME platforms for these genes.
SNP selection
SNP selection was balanced between literature-based evidence
of functionality and apparent signatures of selection. This was
narrowed down to an economic subset of SNPs for which
genotyping assays could be designed on the mass spectrometry
iPLEX platform. Three measures were used to identify signatures
of positive selection; Wright’s Fst [34], haplosimilarity (Hs
measure) [35] and extended haplotype homozygosity (EHH
measure) [36]. In addition to the genic region, up to 10 kb
upstream and downstream of each transcript was investigated (see
Table S3). Signatures of selection were sought using the available
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genotype data from HapMap release no. 19 (http://www.
hapmap.org).
Genotyping methods
Genotyping was undertaken using Sequenom’s mass spectrom-
etry iPLEX gold platform (http://www.sequenom.com). Prior to
genotyping on the Malawian and Gambian samples, the SNP
assays were tested on the Yoruba HapMap parental DNA
samples. Only assays with high concordance (.95%) to the
official HapMap data (http://www.hapmap.org), genotype distri-
butions conforming to Hardy-Weinberg equilibrium at the 0.1%
significance threshold, and high call rates ($90%) were genotyped
on the malaria cases and controls.
Association analysis
Meta-analysis was undertaken across all the case-control and
family studies using the methods outlined in Kazeem and Farrall
[37]. Inter-study heterogeneity in association was assessed using
Cochran’s chi-square test (Q-test) under the null hypothesis of
homogeneity (significant heterogeneity P,0.05). Individual SNPs
were investigated using allele- and genotype-based models. Multi-
allele tests were undertaken using haplotypes. Genotype associa-
tions were tested using pseudo case-control analysis with
correction for HbS using the GenAssoc package (http://www-
gene.cimr.cam.ac.uk/clayton/software/). Associations were cor-
rected for the HbS locus, which exerts a strong influence on severe
malaria outcome [38,39]. In the Malawian and Gambian case-
control studies, associations were tested using logistic regression
analysis and conditional logistic regression with stratification by
ethnicity, respectively. Regression analysis was undertaken in
STATA (STATA, version 9.0; StataCorp, College Station, TX).
In the family trios, association tests were undertaken using the
transmission distortion test (TDT) [40].
Haplotype reconstruction
In the case-control studies, haplotypes were reconstructed using
SNPHAP (http://www-gene.cimr.cam.ac.uk/clayton/software/).
Only haplotypes with SNPHAP probabilities$80% were included
in association analysis. In the family trios, haplotypes were
reconstructed using an Expectation Maximisation algorithm in R.
Supporting Information
Table S1 Individual study and pooled odds ratios of allelic
associations in all genes investigated. Odds ratios corresponding to
severe malaria associations with the minor allele of the given locus
are presented for individual studies and pooled studies (meta-
analysis). Z scores and corresponding P-values are presented for
the pooled associations. Q scores and corresponding P-values are
presented for Cochran’s test of heterogeneity between the studies.
Odds ratios refer to the minor allele at each locus. Cochran’s Q-
test for heterogeneity on 4 degrees of freedom. CC: Case-control.
Found at: doi:10.1371/journal.pone.0010017.s001 (0.30 MB
RTF)
Table S2 Severe malaria subphenotype frequencies. CM:
Cerebral malaria. SA: Severe anaemia.
Found at: doi:10.1371/journal.pone.0010017.s002 (0.04 MB
RTF)
Table S3 Properties of Gs pathway candidates. 1Region
investigated using haplosimilarity (HS) and extended haplotype
homozygosity (EHH) tools for detecting signatures of selection.
Found at: doi:10.1371/journal.pone.0010017.s003 (0.03 MB
RTF)
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